GIL 2026 | The 20th Frost & Sullivan Summit 2026 Conclined Successfully | Focusing on the Period of Innovation Explosion, Shaping a New Future of Transformation and Growth

On August 5, the 20th Frost & Sullivan Global Growth, Innovation and Leadership (GIL) Summit and the 5th New Investment Event (the "2026 Frost & Sullivan Summit" or "Conference"), organized by Frost & Sullivan and co-hosted by LeadLeo, successfully concluded at Jing An Shangri-La Hotel in Shanghai. The event attracted prominent guests from home and abroad, featuring over 150 speeches and panel discussions, with more than 5,000 professional attendees present.

On August 5, the 20th Frost & Sullivan Global Growth, Innovation and Leadership (GIL) Summit and the 5th New Investment Event (the "2026 Frost & Sullivan Summit" or "Conference"), hosted by Frost & Sullivan and co-organized by LeadLeo, successfully concluded at Jing An Shangri-La, Shanghai. The Summit gathered distinguished speakers from China and abroad, featuring more than 150 keynotes and panel discussions, with over 5,000 professional attendees on site.

With the theme "Anchoring the Innovation Explosion, Shaping New Future of Transformational Growth", supported by the China Advertising Association, China Association for Public Companies, Shanghai Federation of Modern Service Industry, Shanghai Information Service Industry Association, Shanghai Yangtze River Delta Modern Industry Development Promotion Association, and Shanghai Consulting Industry Association, the Summit brought together the insights and expertise of the global industry, academia and investment communities to explore new growth drivers, new markets and new tracks for China's economy in the new era. The two-day Summit consisted of one opening ceremony, ten sub-forums and multiple themed events, covering hot topics across the entire sci-tech innovation value chain, including AI advancement, semiconductors and AI infrastructure, new intelligence productivity, life science new investment, synthetic biology and biomanufacturing, new consumption and global expansion, talent education, and high-quality development of listed companies.

With the theme "Anchoring the Innovation Explosion, Shaping New Future of Transformational Growth", and supported by the China Advertising Association, China Association for Public Companies, Shanghai Federation of Modern Service Industry, Shanghai Information Service Industry Association, Shanghai Yangtze River Delta Modern Industry Development Promotion Association, and Shanghai Consulting Industry Association, the Summit brought together the insights and expertise of the global industry, academia and investment communities to explore new growth drivers, new markets and new tracks for China's economy in the new era. The two-day Summit consisted of one opening ceremony, ten sub-forums and multiple themed events, covering hot topics across the entire sci-tech innovation value chain, including AI advancement, semiconductors and AI infrastructure, new intelligence productivity, life science new investment, synthetic biology and biomanufacturing, new consumption and global expansion, talent education, and high-quality development of listed companies.

Meanwhile, the event was broadcast online via Frost & Sullivan WeChat Channel, LeadLeo Video Channel, The Economic Observer, Weibo Health, Choice Data, Peacock Meeting, TF International Securities, iFinD (Hithink RoyalFlush), Jieli TradePro, Futu, Xueqiu, ValueOnline, Whale Platform, Pharma Cafe, and China Machine Press Video Channel.

The Summit was also livestreamed across platforms including Frost & Sullivan WeChat Channel, LeadLeo Video Channel, The Economic Observer, Weibo Health, Choice Data, Peacock Meeting, TF International Securities, iFinD (Hithink RoyalFlush), Jieli TradePro, Futu, Xueqiu, ValueOnline, Whale Platform, Pharma Cafe, and China Machine Press Video Channel.

On the first day, numerous distinguished guests attended the summit, and it concluded successfully with hundreds of participants. Guests from institutions, enterprises and universities presented an inspiring intellectual feast for online and offline audiences. On August 5, the AI-era Talent Development Forum (Industry-Research Integration Practice Focused on Industry Research), Advancement and Leap of AI Forum, and three parallel sessions of the Life Science New Investment Summit — Biopharma, Medical Devices, and Health Tech — as well as the High-Quality Development of Listed Companies Forum, were held as scheduled.

On the first day of the Summit, hundreds of distinguished guests from institutions, enterprises and universities presented an inspiring intellectual feast for online and offline audiences. On August 5, the AI-era Talent Development Forum (Industry-Research Integration Practice Focused on Industry Research), Advancement and Leap of AI Forum, and three parallel sessions of the Life Science New Investment Summit — Biopharma, Medical Devices, and Health Tech — as well as the High-Quality Development of Listed Companies Forum, were held as scheduled.

On August 5, the "Advancement and Leap of AI" sub-forum of the 2026 Frost & Sullivan Summit presented phased achievements in AI technology iteration, industrial implementation and commercial monetization in 2026 across the entire value chain.

On August 5, the "Advancement and Leap of AI" sub-forum of the 2026 Frost & Sullivan Summit presented phased achievements in AI technology iteration, industrial implementation and commercial monetization in 2026 across the entire value chain.

The morning session focused on core foundational areas of the AI industry, covering cutting-edge topics including AI security governance, annual top 10 technology trends, AI chips commercialization, industrialization of embodied intelligence, R&D of human-robot symbiotic systems, industrial value of decision intelligence, and multimodal large models reshaping industrial workflows. Lu Wei, Vice President of the Cybersecurity Association of China, analyzed the achievements of AI security governance system development. Industry speakers including Jeremy Chen from Tencent Cloud, Tian Ye from RoboScience, Wang Xi from Cardinal Operations (Shanghai) Co., Ltd., Li Jing from StepFun, Sun Baigui from Irootech Technology Co., Ltd., Wang Ke from Zhixiang Technology, and Li Niyong from Benyuan Shuzhi shared the latest practical achievements and industrial value in embodied intelligence, decision intelligence, multimodal large models and industrial AI applications.

The morning session focused on core foundational areas of the AI industry, covering cutting-edge topics including AI security governance, annual top 10 technology trends, AI chips commercialization, industrialization of embodied intelligence, R&D of human-robot symbiotic systems, industrial value of decision intelligence, and multimodal large models reshaping industrial workflows. Lu Wei, Vice President of the Cybersecurity Association of China, analyzed the achievements of AI security governance system development. Industry speakers including Jeremy Chen from Tencent Cloud, Tian Ye from RoboScience, Wang Xi from Cardinal Operations (Shanghai) Co., Ltd., Li Jing from StepFun, Sun Baigui from Irootech Technology Co., Ltd., Wang Ke from Zhixiang Technology, and Li Niyong from Benyuan Shuzhi shared the latest practical achievements and industrial value in embodied intelligence, decision intelligence, multimodal large models and industrial AI applications.

The afternoon session focused on AI frontier technology innovation, AI Native product innovation and industrial commercialization practices, covering hot topics including brain-computer interface technology leaps, AI Native product system building, programmable RNA design, and AI enterprises赴港上市 valuation logic.

The afternoon session focused on cutting-edge AI technology innovation, AI-native product innovation, and industrial commercialization practices, covering hot topics including brain-computer interface technology leaps, AI Native product system building, programmable RNA design, and valuation logic for AI enterprises listing in Hong Kong.

Among them, the product lead of Tencent's hit product WorkBuddy shared organizational insights behind building AI Native products from 0 to 1, analyzing practical paths of AI native products in organizational collaboration, product design and commercial implementation, providing a reference model for enterprises advancing AI Native product innovation. The forum saw the release of multiple major research outcomes, including the Global Brain-Computer Interface Industry Development White Paper（2026）, 2026 China AI Advancement and Leap White Paper, Decision Intelligence: Reshaping the Industrial Economy as the "Third Pole of AI", Embodied Sensors: The Perception Foundation of Intelligent Robots, Global Embodied AI Technology Innovation and Application White Paper, 2026 Best Application Practices for Marketing in an AI Environment, & 2026 China AI Agent Best Practice Rankings, systematically outlining the latest research and development trends in AI technology evolution, decision intelligence, embodied intelligence, robot perception and AI marketing applications, providing important reference for industrial innovation, technology implementation and commercial practice.

Notably, the product lead of Tencent's hit product WorkBuddy shared organizational insights behind building AI Native products from 0 to 1, analyzing practical paths of AI native products in organizational collaboration, product design and commercial implementation, providing a reference model for enterprises advancing AI Native product innovation. The forum saw the release of multiple major research outcomes, including the Global Brain-Computer Interface Industry Development White Paper（2026）, 2026 China AI Advancement and Leap White Paper, Decision Intelligence: Reshaping the Industrial Economy as the "Third Pole of AI", Embodied Sensors: The Perception Foundation of Intelligent Robots, Global Embodied AI Technology Innovation and Application White Paper, 2026 Best Application Practices for Marketing in an AI Environment, & 2026 China AI Agent Best Practice Rankings, systematically outlining the latest research and development trends in AI technology evolution, decision intelligence, embodied intelligence, robot perception and AI marketing applications, providing important reference for industrial innovation, technology implementation and commercial practice.

Meanwhile, the 2026 China AI Agent（智能体）Best Practice Rankings was also officially released. Evaluated across dimensions including technological innovation capability, scenario implementation results, commercial application value and industry demonstration significance, the list systematically selected outstanding representative products and application practices in China's AI Agent sector, showcasing implementation achievements and benchmark cases, and providing actionable practical reference for industrial intelligent upgrading and large-scale AI Agent application. Two panel discussions also provided an in-depth exploration of domestic AI technology breakthrough paths amid China-US AI industry competition, and commercialization paths and practical experience for unlocking AI business value, fully covering AI technology, industry, capital and governance, and comprehensively demonstrating the advancements and future development potential of China's AI industry.

The 2026 China AI Agent Best Practice Rankings was also officially released. Evaluated across dimensions including technological innovation capability, scenario implementation results, commercial application value and industry demonstration significance, the list systematically selected outstanding representative products and application practices in China's AI Agent sector, showcasing implementation achievements and benchmark cases, and providing actionable practical reference for industrial intelligent upgrading and large-scale AI Agent application. Two panel discussions also provided an in-depth exploration of domestic AI technology breakthrough paths amid China-US AI industry competition, and commercialization paths and practical experience for unlocking AI business value, fully covering AI technology, industry, capital and governance, and comprehensively demonstrating the advancements and future development potential of China's AI industry.

This forum was hosted by Prof. Wang Yu, Chairman, Chinese Foundation for Hepatitis Prevention and Control, and Dr. Liu Wei, Co-founder of Hysigel Biotechnology. It focused on innovative drug R&D breakthroughs, technology iteration, global footprint and capital investment logic, gathering industry leaders, research institutions, investment banks and industry experts for in-depth discussion. Jacqueline Jiang, Vice President, HKEX, detailed support policies and listing opportunities for biopharma enterprises in the Hong Kong capital market; Prof. Chen Shaoxiong, Executive President & Secretary- General, Shanghai Biopharmaceutics Industry Association reviewed the high-quality development landscape of biopharma industry in Shanghai and nationwide; Dr. Zhang Lianshan, Executive Vice President & Director, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) shared practical strategies for leading pharma enterprises to build innovative R&D systems and global footprint.

This session was moderated in turn by Prof. Wang Yu, Chairman, Chinese Foundation for Hepatitis Prevention and Control, and Dr. Liu Wei, Co-founder of Hysigel Biotechnology. Focused on innovative drug R&D breakthroughs, technology iteration, global footprint and capital investment logic, the session gathered industry leaders, research institutions, investment banks and industry experts for in-depth discussion. Jacqueline Jiang, Vice President, HKEX, detailed support policies and listing opportunities for biopharma enterprises in the Hong Kong capital market; Prof. Chen Shaoxiong, Executive President & Secretary- General, Shanghai Biopharmaceutics Industry Association reviewed the high-quality development landscape of biopharma industry in Shanghai and nationwide; Dr. Zhang Lianshan, Executive Vice President & Director, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) shared practical strategies for leading pharma enterprises to build innovative R&D systems and global footprint.

The forum officially released two authoritative reports: China Biopharma International Development Blue Book (2026) and Global Gene Therapy Industry Development Blue Book (2026). Representatives from enterprises including WestGene Biopharma, Hysigel Biotechnology, Handing Pharmaceuticals, and Syneron Bio shared cutting-edge achievements in CAR-T cell therapy, 3D cell intelligent manufacturing, PDC new drug R&D, and AI-empowered peptide drug R&D. Two panel discussion featured in-depth exchanges on "co-building global ecosystem for Chinese innovative drugs" and "AI-empowered biopharma R&D innovation", gathering representatives from Morgan Stanley, CITIC Securities, MindRank, and TandemAI, comprehensively reviewing innovation achievements of China's biopharma industry, and accurately interpreting globalization development paths and capital investment opportunities.

The forum officially released two authoritative reports: China Biopharma International Development Blue Book (2026) and Global Gene Therapy Industry Development Blue Book (2026). Representatives from enterprises including WestGene Biopharma, Hysigel Biotechnology, Handing Pharmaceuticals, and Syneron Bio shared cutting-edge achievements in CAR-T cell therapy, 3D cell intelligent manufacturing, PDC new drug R&D, and AI-empowered peptide drug R&D. Two panel discussion featured in-depth exchanges on "co-building global ecosystem for Chinese innovative drugs" and "AI-empowered biopharma R&D innovation", gathering representatives from Morgan Stanley, CITIC Securities, MindRank, and TandemAI, comprehensively reviewing innovation achievements of China's biopharma industry, and accurately interpreting globalization development paths and capital investment opportunities.

2026 Frost & Sullivan Summit – "Innovation Without Bounds, Device Leadership" life science new investment summit parallel session medical devices session was successfully held, moderated by Yuan Chengfei, Partner, Tax and Business Consulting Department, PwC China, Shanghai Office, with opening remarks by Fred Mao, Senior Partner & Managing Director of Frost & Sullivan China. In the morning session, Neusoft Medical, Bridges Capital, Hangzhou Neureal Technology Co., Ltd., and BRATTEA delivered keynotes on the integration of high-end medical devices and AI, industry investment and financing landscape, non-invasive brain-computer interfaces, and minimally invasive intervention and chronic disease management; the following panel, moderated by Wang Yinyan, Executive Director, CICC, gathered Dr. Mao Wen, Chairman of the board & CEO, Nanjing Novlead Biotechnology Co., Ltd., Dr.Tsai Tsung-yuan, CEO, Shanghai TAOiMAGE Medical Tech.Co.,Ltd, and representatives from Lifeshield Medical, Mindtrix Technology Co., Ltd., and Proxima Capital, discussing technology translation and global expansion pace under the theme "From Clinical Innovation Breakthrough to Global Expansion".

At the 2026 Frost & Sullivan Summit, the "Innovation Without Bounds, Device Leadership" medical device parallel session of the Life Science New Investment Summit was successfully held, moderated by Yuan Chengfei, Partner, Tax and Business Consulting Department, PwC China, Shanghai Office, with opening remarks by Fred Mao, Senior Partner & Managing Director of Frost & Sullivan China. In the morning session, Neusoft Medical, Bridges Capital, Hangzhou Neureal Technology Co., Ltd., and BRATTEA delivered keynotes on the integration of high-end medical devices and AI, industry investment and financing landscape, non-invasive brain-computer interfaces, and minimally invasive intervention and chronic disease management; the following panel, moderated by Wang Yinyan, Executive Director, CICC, gathered Dr. Mao Wen, Chairman of the board & CEO, Nanjing Novlead Biotechnology Co., Ltd., Dr.Tsai Tsung-yuan, CEO, Shanghai TAOiMAGE Medical Tech.Co.,Ltd, and representatives from Lifeshield Medical, Mindtrix Technology Co., Ltd., and Proxima Capital, discussing technology translation and global expansion pace under the theme "From Clinical Innovation Breakthrough to Global Expansion".

The afternoon session began with a presentation by Mei Minfei, Strategy Director, KANTE (Shenzhen) Biotechnology Co., Ltd. on "early cancer detection and insurance reimbursement systems", followed by presentations on frontline progress by TowardPi (Beijing) Medical Technology Ltd., Shanghai Medical Image Insights Intelligent Technology Co., Ltd., AccuPulse Medical Device (Zhejiang) Ltd., DK Medical Technology, Nanjing Nuoyuan Medical Device Co., Ltd., and HBNCT Technology (Hangzhou) Co., Ltd. on ophthalmic devices, medical imaging AGI, cardiac electrophysiology, breakthroughs in the post-centralized procurement era, fluorescence-guided surgery and BNCT; the closing panel, moderated by Li Yingwen, General Manager of the Healthcare Industry Group, Investment Banking Division, GF Securities Moderator, gathered Huake Pioneer, Nanovision Technology Group, Shanghai StairMed Medical Technology Co., Ltd, Lifemotion Medical Technology Co., Ltd, and Baheal Zhongxin Capital to discuss device innovation cooperation models.

The afternoon session began with a presentation by Mei Minfei, Strategy Director, KANTE (Shenzhen) Biotechnology Co., Ltd. on "early cancer detection and insurance reimbursement systems", followed by presentations on frontline progress by TowardPi (Beijing) Medical Technology Ltd., Shanghai Medical Image Insights Intelligent Technology Co., Ltd., AccuPulse Medical Device (Zhejiang) Ltd., DK Medical Technology, Nanjing Nuoyuan Medical Device Co., Ltd., and HBNCT Technology (Hangzhou) Co., Ltd. on ophthalmic devices, medical imaging AGI, cardiac electrophysiology, breakthroughs in the post-centralized procurement era, fluorescence-guided surgery and BNCT; the closing panel, moderated by Li Yingwen, General Manager of the Healthcare Industry Group, Investment Banking Division, GF Securities Moderator, gathered Huake Pioneer, Nanovision Technology Group, Shanghai StairMed Medical Technology Co., Ltd, Lifemotion Medical Technology Co., Ltd, and Baheal Zhongxin Capital to discuss device innovation cooperation models.

During the forum, the "Global Brain-Computer Interface Industry Development White Paper" and "2026 Global Digital Medicine Imaging Industry Development Blue Book" were also released.

Meanwhile, the forum released the Global Brain-Computer Interface Industry Development White Paper and Global Digital & Intelligent Medical Imaging Ecosystem Industry Development Blue Book (2026).

Life Science New Investment Summit Parallel Session – Health Tech Session

Life Science New Investment Summit Parallel Session: Health Tech

This sub-forum was co-hosted by Frost & Sullivan, TradeGo FinTech Limited, Cloud Technology, Golden Continent Holdings Limited, and Grandway Law Offices, with support from the Overseas Chapter of the China Association for Public Companies. Against the dual backdrop of AI technology revolution and capital market reform, the forum focused on core topics including high-quality development of listed companies, capital operation, global layout and compliance risk control. China Association for Public Companies clarified that listed companies are the core vehicles for cultivating new quality productive forces; Hong Kong Stock Exchange shared new trends of Hong Kong market reform; sci-tech enterprises including Unisound AI Technology, Robotphoenix Intelligent Technology, Nanjing Chuhang Technology Co., Ltd., and UBTech Robotics showcased achievements in AI implementation and industrial upgrading; Grandway Law Offices, Golden Continent Holdings Limited, Ant Digital Technologies, and Dalipal Holdings Limited contributed professional insights on risk control in overseas M&A, Hong Kong stock investment strategies, and global expansion practice.

This sub-forum was co-hosted by Frost & Sullivan, TradeGo FinTech Limited, Cloud Technology, Golden Continent Holdings Limited, and Grandway Law Offices, with support from the Overseas Chapter of the China Association for Public Companies. Against the dual backdrop of AI technology revolution and capital market reform, the forum focused on core topics including high-quality development of listed companies, capital operation, global layout and compliance risk control. China Association for Public Companies clarified that listed companies are the core vehicles for cultivating new quality productive forces; Hong Kong Stock Exchange shared new trends of Hong Kong market reform; sci-tech enterprises including Unisound AI Technology, Robotphoenix Intelligent Technology, Nanjing Chuhang Technology Co., Ltd., and UBTech Robotics showcased achievements in AI implementation and industrial upgrading; Grandway Law Offices, Golden Continent Holdings Limited, Ant Digital Technologies, and Dalipal Holdings Limited contributed professional insights on risk control in overseas M&A, Hong Kong stock investment strategies, and global expansion practice.

There were 13 keynote speeches and 2 panel discussions throughout the day, creating an efficient communication platform among regulatory authorities, exchanges, listed companies, and professional services institutions, providing practical and forward-looking guidance for Chinese enterprises to seize opportunities in global competition.

The forum featured 13 keynote speeches and 2 panel discussions throughout the day, creating an efficient exchange platform among regulators, exchanges, listed companies, and professional service institutions, providing practical forward-looking guidance for Chinese enterprises to seize transformation opportunities in global competition.

With this, the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Event successfully concluded.

With this, the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Event successfully concluded.

Dr. Neil Wang, Global Senior VP, Co-Chairman of Asia Pacific, and Chairman of China, Frost & Sullivan, stated: "Frost & Sullivan's mission is to communicate China's growth, innovation and leadership to the world, helping the world clearly understand China's value, and helping China embrace global opportunities faster. The Frost & Sullivan Summit has a history of over 30 years globally, and has been successfully held for 20 consecutive years in China, rain or shine. Going forward, we will uphold our commitment of being based in Shanghai, serving China, and remaining globally oriented, and pursuing win-win cooperation, helping enterprises achieve domestic and global growth strategies, empowering industrial transformation and upgrading through sci-tech innovation, cultivating leadership among Chinese entrepreneurs, and ultimately promoting high-quality economic and social development in China."

Dr. Neil Wang, Global Senior VP, Co-Chairman of Asia Pacific, and Chairman of China, Frost & Sullivan, stated: "Frost & Sullivan's mission is to communicate China's growth, innovation and leadership to the world, helping the world clearly understand China's value, and helping China embrace global opportunities faster. The Frost & Sullivan Summit has a history of over 30 years globally, and has been successfully held for 20 consecutive years in China, rain or shine. Going forward, we will uphold our commitment of being based in Shanghai, serving China, and remaining globally oriented, and pursuing win-win cooperation, helping enterprises achieve domestic and global growth strategies, empowering industrial transformation and upgrading through sci-tech innovation, cultivating leadership among Chinese entrepreneurs, and ultimately promoting high-quality economic and social development in China."

Frost & Sullivan will continue to work with all partner institutions to accelerate enterprise growth, help enterprises achieve benchmark positions in growth, innovation and leadership in their industries, and together with all partners, capitalize on the boom in innovation and shape a new future of transformational growth.

Frost & Sullivan will continue to work with all partner institutions to accelerate enterprise growth, help enterprises achieve benchmark positions in growth, innovation and leadership in their industries, and together with all partners, capitalize on the boom in innovation and shape a new future of transformational growth.

We will meet again next year!

See you next year!